459
Participants
Start Date
October 25, 2013
Primary Completion Date
September 17, 2019
Study Completion Date
September 17, 2019
MEDI4736
MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb).
Tremelimumab
Tremelimumab is an anti-CTLA4 monoclonal antibody (mAb).
tremelimumab
Tremelimumab is an anti-CTLA4 monoclonal antibody (mAb).
Research Site, Tainan City
Research Site, Brussels
Research Site, Darlinghurst
Research Site, Kogarah
Research Site, Gosford
Research Site, Liège
Research Site, Ghent
Research Site, New York
Research Site, Taipei
Research Site, New York
Research Site, Marseille
Research Site, Seongnam-si
Research Site, Newark
Research Site, Rozzano
Research Site, Milan
Research Site, Saronno
Research Site, Dijon
Research Site, Baltimore
Research Site, Fairfax
Research Site, Jaén
Research Site, Sondrio
Research Site, Morgantown
Research Site, Madrid
Research Site, Madrid
Research Site, Huntersville
Research Site, Cheongju-si
Research Site, Málaga
Research Site, Bordeaux
Research Site, Tampa
Research Site, Montpellier
Research Site, La Tronche
Research Site, Bologna
Research Site, Seville
Research Site, Columbus
Research Site, Saint-Herblain
Research Site, Valencia
Research Site, Indianapolis
Research Site, Ann Arbor
Research Site, Detroit
Research Site, Siena
Research Site, Lille
Research Site, St Louis
Research Site, Lyon
Research Site, Tyler
Research Site, Fort Worth
Research Site, Houston
Research Site, Aurora
Research Site, Tucson
Research Site, Los Angeles
Research Site, Los Angeles
Research Site, San Francisco
Research Site, Portland
Research Site, Seattle
Research Site, Birmingham
Research Site, New Haven
Research Site, Boston
Research Site, Boston
Research Site, Lebanon
Research Site, Incheon
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Barcelona
Research Site, Barcelona
Research Site, London
Research Site, Manchester
Lead Sponsor
MedImmune LLC
INDUSTRY